key: cord-1056523-hsfg9tje authors: Kumar, Akash; Chattopadhyay, Ankita; Gupta, Snehil title: Neuropsychiatric manifestation of the drugs used in the treatment of SARS-2-CoV-2019 (COVID-19) infection and their management: An overview and practice implications. date: 2022-04-06 journal: Asian J Psychiatr DOI: 10.1016/j.ajp.2022.103101 sha: 5bab2fe4b337ffff546a182948cd35cb709aeed2 doc_id: 1056523 cord_uid: hsfg9tje Treatment guidelines for the COVID-19 treatment are still evolving, moreover, the changing variants of the virus with varying virulence, pose challenges for the healthcare professionals (HCP) not only in managing the primary infection but also a myriad of physical and neuropsychiatric complications. The neuropsychiatric adverse consequences associated with the COVID-19 are attributable to the direct effect of the virus, secondary complications, drug-drug interaction, and neuropsychiatric manifestations of drugs used in its treatment. These neuropsychiatric manifestations not only complicate the ongoing treatment but also adversely affect the prognosis. As the treatment guidelines for the management of the COVID are still evolving, the use of non-evidence-based medications, including their off-label use, are rampant that often extend to their non-judicious or irrational use (more than the recommended dose, multiple medications, etc.). Despite the significance of the topic, literature is sparse. Knowing about the risk factors and the potential neuropsychiatric adverse effects with various anti-COVID-19 medications would help HCPs in effectively preventing, early identifying, and promptly managing these neuropsychiatric symptoms. Therefore, this narrative review is aimed to highlight the neuropsychiatric symptoms associated with medications/interventions used in the management of COVID-19 and how to manage them, especially in view of the world facing the third wave of COVID-19. Neuropsychiatric (NP) manifestations are common among patients of COVID-19 infection both during the illness and post-recovery, especially in case of severe illness (García et al., 2020; Helms et al., 2020; Mao et al., 2020) . Common neuropsychiatric symptoms include anxiety (and related disorders), mood disorders, headache, insomnias, delirium, pain, seizures, movement disorder, suicidal ideations, etc. (Nalleballe et al., 2020) . The proposed mechanisms are direct neurotoxicity by the virus, associated psychosocial stressors, the impact of the co-occurring medical or psychiatric comorbidities, COVID-19 treatmentrelated, etc. Clinical presentation and course of the COVID-19 illness has varied across the first two waves of the pandemic: a higher prevalence of illness among the young, higher secondary infection (e.g., mucormycosis and associated morbidity and mortality) in the second wave (Vs first wave), etc. (Asrani et al., 2021; Conde Cardona et al., 2020) . The COVID-19 infections and associated neuropsychiatric manifestations pose a significant challenge to the healthcare professionals (HCPs). Particularly, immunomodulatory agents (hydroxychloroquine, ivermectin, remdesivir, systemic steroids, etc.) are associated with greater and severe symptoms such as delirium, psychosis, mood symptoms, anxiety, etc. (Jansen van Vuren et al., 2021) . Notably, the pediatric population is more likely (than adults) to develop these neuropsychiatric symptoms (Orsini et al., 2020) . The national guideline on the management of COVID-19, based on the severity of the symptoms, recommend various agents such as antipyretics like acetaminophen; antitussives; ivermectin, hydroxychloroquine/chloroquine, azithromycin, doxycycline; inhalational budesonide, methylprednisolone, dexamethasone; unfractionated heparin or low molecular weight heparin (UF/LMWH); remdesivir, tocilizumab; convalescent plasma, etc.(Clinical Guidance for Management of adult COVID-19 patients, AIIMS Delhi, 2021) . As the treatment guidelines are evolving and efficacy data on these treatments is still scarce, non-judicious use of medications (prednisolone; remdesivir; hydroxychloroquine, J o u r n a l P r e -p r o o f immunomodulators, etc.) are rampant (Leroy, 2020; Ved, 2021) , resulting in greater neuropsychiatric adverse events (A/Es) among patients. However, these symptoms, particularly medications-induced neuropsychiatric A/Es, often remain unrecognized; while these symptoms pose significant management difficulties, including higher morbidity and mortality (Nalleballe et al., 2020) . Therefore, the clinicians must remain aware of these A/Es, including how to prevent, and identify early, and manage them (Kalil, 2020) . Although there is ample literature on the neuropsychiatric consequences of the COVID-19 infection and its association with comorbid psychiatric illnesses, including drug-drug interaction (psychotropic drugs and COVID-19 medications), data is scarce on COVID-19 treatment-induced neuropsychiatric manifestations. Availability of such literature would guide the clinicians in rational drug prescription, thereby having primary and secondary preventive implications. Moreover, this becomes particularly important when the world is facing the third wave of the COVID-19 pandemic. Therefore, the current review aims to highlight the neuropsychiatric symptoms associated with the medications used in the treatment of the COVID-19 and their management. A literature search was undertaken, including visiting the websites of various international (National Institute of Health, National Institute of Clinical Excellence, Infectious Diseases Society of America) and national agencies (All India Institute of Medical Sciences, Delhi, Indian council of medical research (ICMR), etc.) to enlist the medications commonly used in the treatment of the COVID-19 infections and related complications. Furthermore, drugs that are often used off-label or those approved for compassionate use were also considered. Keywords/search terms used were drug's name ("Ivermectin", "hydroxychloroquine", "prednisolone", etc.) and "adverse effects"/"neuropsychiatric effects"/"adverse effects in COVID-19" in google scholar and PubMed. (Supplementary file 1). The pharmacological properties of these agents were also reviewed through the published journal articles, standard textbooks, and relevant documents provided by the government bodies (AIIMS Covid Information Portal, n.d.; Indian Council of Medical Research, n.d.) J o u r n a l P r e -p r o o f and academic agencies (National institute of Health, 2021; World Health Organization., 2021). The findings have been described in terms of pharmacokinetics and pharmacodynamics of drugs used in the management of the COVID-19 and its complications, their level of evidence for use in COVID-19 infection, adverse drug reactions (mainly neuropsychiatric symptoms), and management (detail in table 1). Following this, a general approach to prevent and manage neuropsychiatric A/Es has also been provided (Table 2) . The medications have been described as per the following pharmacological groups: antimicrobial agents (anti-parasitic, antibacterial, antivirals, antifungals; glucocorticoids; immunomodulators;) and miscellaneous. Evidence for COVID-19 Infection: Because of lack of definitive evidence, the NIH does not recommend or advise against its use in patients suffering from COVID-19 disease. (National institute of Health, 2021). Precautions and Adverse neuropsychiatric Effects: The common neuropsychiatric adverse effects (A/Es) (data from the treatment of helminthic infections) are weakness, increased sleep, headache (10%), dizziness (7.5%) (Chandler, 2018) . Additionally, encephalopathies/delirium, psychotic disorders (Mohapatra & Sahoo, 2015) , suicidal behavior (Kaur et al., 2017) have been reported with its use (Campillo et al., 2021) . Management of neuropsychiatric A/Es: Literature does not state any specific guidelines to manage the above A/Es. However, risk assessment, avoiding higher than recommended doses, monitoring for the above symptoms, and stopping the drug if any A/Es emerge is important. Evidence for COVID-19 Infection: Although, azithromycin is frequently used for its potential role in preventing/treating secondary bacterial infection among COVID-19 patients (Butler et al., 2021) , it is not FDA approved for COVID-19, and NIH does not recommend its use in COVID-19 patients (National institute of Health, 2021). individual to develop a series of cardiac problems (QT prolongation, arrhythmia, and death) (Katzung, 2015) . They also, though rarely, cause neuropsychiatric symptoms like psychosis, delirium, hallucinations, particularly in elderlies (Skelly et al., 2019; The Medical Letter, 2008) . Other rare ADRs include headache, dizziness, sleep disturbances, seizures, choreoathetosis, etc. (Turjanski & Lloyd, 2005) . Precautions and Adverse neuropsychiatric Consequences: The most common ADRs are related to the gastrointestinal system (Katzung, 2015) . Furthermore, likewise with azithromycin, it can rarely cause suicidality and pseudotumor cerebri among the patients (Skelly et al., 2019) . Management of neuropsychiatric A/Es: Pseudotumor cerebri and suicidality may require stoppage of the implicating agents and addition of other medications if symptoms do not subside (Skelly et al., 2019) . General principles of treatment of neuropsychiatric symptoms remain as discussed previously (Turjanski & Lloyd, 2005 Precautions and Adverse neuropsychiatric Consequences: ADRs due to AMB can be immediate (infusion-related toxicity) or delayed (cumulative toxicity). Intrathecal use has been associated with seizures or other neurologic sequelae (Katzung, 2015) . Notably, headache is a more common A/E with both types of formulations. Specifically, conventional formulations are associated with neurotoxicity, parkinsonism, and seizures, whereas lipid formulations are associated more with confusion, sleep problems, fatigue, delirium, and dizziness (Ouyang et al., 2013) . It is a new triazole antifungal drug (Katzung, 2015) . (Ouyang et al., 2013) . Management of neuropsychiatric manifestations of Antifungals: The general principles of management should be followed i.e., discontinuation or decreasing the dose of the drug, or in a few cases, psychotropics may be required (Turjanski & Lloyd, 2005) . Drugs used from this group include dexamethasone, prednisolone, methylprednisolone, and inhalational budesonide Evidence for COVID-19 Infection: The Infectious Disease Society of America (IDSA) guideline panel strongly recommends oral/parenteral dexamethasone 6 mg (or equivalent doses of other glucocorticoids) for hospitalized severe or critically ill COVID-19 positive patients. Precautions and Adverse neuropsychiatric Consequences: Systemic corticosteroids are known to cause neuropsychiatric A/Es. Usually, in COVID-19 illness, following a short course of high-dose corticosteroid treatment (>20 mg/day prednisone for three months), delirium and mood changes (manic/hypomanic episodes> depression) have been reported (with prevalence as high as 52%) (Fardet et al., 2007) . Memory deficits, cognitive impairment, agitation, and anxiety are other notable ADRs (Borah et al., 2021; Ou et al., 2018) ; they can also trigger seizures (Jarrahi et al., 2020; van Campen et al., 2018) . Literature from the SARS-virus pandemic (2005) reports that corticosteroids account for 29.9%, 2.9%, and 18% of variances in anxiety, depression, and psychosis, respectively (Sheng et al., 2005) . Furthermore, higher doses of steroid use have been associated with an increased incidence of psychotic symptoms among individuals suffering from the COVID-19 . In previous reports of acute SARS-CoV-2 infection, mania and psychosis were found to occur only in a small minority (0·7%), but it was almost entirely associated with the use of exogenous corticosteroids. However, reduced sleep, emotional lability, irritability, pressured speech, and euphoria were more commonly reported instead of a full-fledged picture of mania (Rogers et al., 2020; Sheng et al., 2005) . Management of neuropsychiatric A/Es: Patients with COVID-19 receiving corticosteroids, especially in high doses and for long-duration, should be strictly monitored for these symptoms. Literature suggests that neuropsychiatric symptoms associated with the corticosteroids disappear after the tapering or stoppage of the drugs (Kahn et al., 1988; Wada et al., 2001) . Whenever required, mood-stabilizers, such as lithium and valproic acid, or atypical antipsychotics like olanzapine, etc. should be used (Zagaria, 2016) . Notably, carbamazepine induces steroids metabolism, thereby reducing the neurotoxic effects of the latter (Hall et al., 1978) Corticosteroid-induced depressive episodes respond better to selective serotonin reuptake inhibitors, such as fluoxetine, or other drugs like lamotrigine, risperidone, quetiapine, and gabapentin, however, tricyclic antidepressants may worsen it (Wada et al., 2001; Wyszynski & Wyszynski, 1993) . Evidence for COVID-19 Infection: The Steroids in COVID-19 (STOIC) trial, a phase 2, open-label trial (Active arm received budesonide (800μg) in divided doses; controlled arm received treatment as usual) reported an early administration of budesonide significantly reduce the likelihood of COVID-19 related urgent medical care and also decreased time to recovery (Ramakrishnan et al., 2021) . Precautions and Adverse neuropsychiatric Consequences: There are some case reports of hyperactivity, impairment in concentration, mania, and insomnia, particularly in the pediatric population, with the use of budesonide (Connett & Lenney, 1991; Lewis & Cochrane, 1983) . Literature involving the pediatric population found about 15% of their samples experienced some neuropsychologic A/Es (Hederos, 2004) . These symptoms are more frequent in female adolescents (vs. males) and were dose-dependent (Hergüner et al., 2006) . first few days of starting inhalational budesonide, and get resolved upon tapering or discontinuing the drug (Alotaibi & Alshammari, 2012) . Tocilizumab Evidence for COVID-19 Infection: IDSA guideline panel suggests tocilizumab in addition to standard of care (i.e., steroids) among hospitalized adults with progressive severe or critical COVID-19 illness (Bhimraj et al., 2020) . Precautions and Adverse neuropsychiatric Consequences: Headache, dizziness, peripheral neuropathy, leukoencephalopathy, cognitive impairment, demyelinating disorders, depression have been reported with the use of tocilizumab in chronic inflammatory conditions (Borah et al., 2021) . Reports on adverse neuropsychiatric symptoms in COVID-19 with its use are, however, lacking; in contrast, tocilizumab has been found to improve cognition in individuals suffering from schizophrenia (Miller et al., 2016) . Slow titration of the dose of the tocilizumab can be a preventive strategy against the development of neuropsychiatric A/Es. Management of neuropsychiatric A/Es: Decreasing the dose or stopping it, whenever required, could revert these symptoms. Furthermore, a low dose of psychotropic medications for a shorter duration can be used to treat these symptoms, particularly when stopping the drug is not possible. Bamlanivimab/Etesevimab, Casirivimab/Imdevimab; and Baricitinib Evidence for COVID-19 Infection: The IDSA guideline panel recommends bamlanivimab/etesevimab or casirivimab/imdevimab in ambulatory patients with mild to moderate COVID-19 illness who are at high risk for progression to severe disease. It also strongly recommends against bamlanivimab monotherapy in hospitalized patients with severe COVID-19. The combination of casirivimab and imdevimab and bamlanivimab and etesevimab have been approved by the FDA while bamlanivimab monotherapy has been revoked. IDSA also recommends baricitinib plus remdesivir plus corticosteroids for hospitalized patients (Bhimraj et al., 2020) . Precautions and Adverse neuropsychiatric consequences: There is no reported neuropsychiatric adverse effect with these agents. Evidence for COVID-19 Infection: Severe COVID-19 illness results in a hypercoagulable state and is associated with a poorer prognosis (Tang et al., 2020) , therefore, heparin is usually recommended among hospitalized COVID-19 patients (Gozzo et al., 2020) . Precautions and Adverse neuropsychiatric Consequences: Although heparin, per se, does not cause neuropsychiatric symptoms, it can have significant pharmacokinetic interaction with the psychotropic agents, particularly with the SSRIs, latter can cause platelet dysfunction, thereby may worsen the risk of bleeding (Taylor, Barnes, and Young, 2018) Management of neuropsychiatric A/Es: A clinician should be cautious while using psychotropic medications with heparin; may consider switching to other psychotropic agents that have lesser interaction with the heparin. Precautions and Adverse Neuropsychiatric Consequences: At the usual dose, it is well tolerated. At higher doses, it may cause dizziness, excitement, and disorientation (Katzung, 2015) . Although neuropsychiatric A/Es are rare with acetaminophen (and with other Nonsteroidal anti-inflammatory drugs, mood symptoms, sleep problems, cognitive changes, worsening, or in some cases, precipitation of psychiatric conditions including psychosis have been reported (Gupta & Chadda, 2016; The Medical Letter, 2008) . Management of Neuropsychiatric A/Es: Avoiding the higher dose of acetaminophen, particularly in at-risk patients, including those with a history of psychiatric illness or on hepatotoxic drugs such as valproate, carbamazepine, chlorpromazine, etc. (Onder et al., 2004) . A newer modality of treatment such as plasma therapy has been recommended for patients having severe illness and requiring ICU care. Though data is not available on their neuropsychiatric A/Es, pharmacovigilance and mandatory reporting must be exercised to identify them. To prevent the development of medications-induced the neuropsychiatric A/Es among COVID-19 patients, healthcare professionals (HCPs) must remain aware of these potential J o u r n a l P r e -p r o o f neuropsychiatric A/Es (details in table 2). One needs to be vigilant, particularly while dealing with the at-risk individuals (with multiple medical comorbidities, past or current history of psychiatric illness, elderlies) and while using systematic steroids, immunomodulators, etc. (Gupta & Chadda, 2016) . Rational use of evidence-based medications is crucial concerning this. Likewise, early identification and prompt management of these conditions are vital.